The growth and recurrence of a number of cancers is driven by a scarce population of cancer stem cells (CSCs), which are resistant to most current therapies. It has been shown previously that Natural Killer (NK) cells recognize human glioma, melanoma, colon and prostate CSCs in vitro.
Introduction
The last century has seen a great deal of speculation as to the processes underlying the etiology of cancer and several theories have been put forward.
1, 2 The fact that any cell exposed to genotoxic stress is able to generate a tumor has received general agreement. 3 Meanwhile, stochastic influences have more recently been found to be major contributors to cancer development. They are nowadays often considered more important than either hereditary or external environmental factors. Most genomic changes occur simply by chance during DNA replication. Considering the number of mutations needed for malignant transformation, it appears highly plausible that these can only accumulate in long-lived cells, i.e. stem cells. 4 Cancer stem cells (CSCs) have recently been proposed as a key compartment of the tumor population. 5, 6 Similarly to normal stem cells, CSCs are a slowly proliferating population which is able to self-renew and give rise to more differentiated cells that compose the bulk of a tumor. 7 CSCs have also been hypothesized to be a crucial factor in tumor recurrence, due to their intrinsic resistance to drugs and irradiation which often enables them to survive traditional therapies.
Moreover, they have been demonstrated to be responsible for the hematological metastatic spread of solid tumors. 8 Therefore, the question of whether cells of the CSC phenotype and tumorigenic potential are common or rare within human cancers has fundamental implications for therapy. 9 If tumorigenic cells are a small minority population, as suggested by the cancer stem cell theory, 10, 11 improved anti-cancer therapies may be identified based on their ability to kill CSCs, rather than the bulk population of non-tumorigenic cancer cells. 12, 13 It is furthermore wise to explore whether effector immune cytotoxic cells (NK cells, CD8 T cells and γδ T cells) can be used to eliminate the tumor stem cell compartment in order to limit the CSC contribution to sustaining tumor progression. The low levels of MHC class I expression reported in CSCs hints at the low efficiency of CSC targeting by CD8 T lymphocytes. 14, 15 However, the expression of ligands for NK activating receptors (NKG2D, NCR and DNAM-1) [15] [16] [17] 23 and murine and human triple negative breast cancer (TNBC) cell lines.
Results and Discussion
Tumorspheres derived from the murine ErbB2 + tumor cell line, TUBO, were used to evaluate whether NK cells are able to recognize breast cancer derived CSCs. CSC enrichment in tumorspheres was confirmed via the increased percentage of cells that were positive for aldehyde dehydrogenase (ALDH) activity and for stem cell markers, Sca-1 and Thy1.1, as compared to TUBO parental cells ( Fig. 1A and B, respectively), as has already been observed in previous reports. 22, 24 Moreover, tumorspheres showed increased in vitro self-renewal, with respect to TUBO cells in our own experiments. This is demonstrated by the higher number of cell clones generated by tumorspheres in a limiting dilution assay (Fig. 1C) , confirming that they possess higher enrichment in CSCs than TUBO cells. Injecting TUBO and tumorspheres s.c. into BALB/c mice led to the observation that 1x10 3 tumorsphere-derived cells gave rise to a fast growing palpable tumor in 100% mice, while the same number of TUBO cells induced a palpable tumor in only 66.7% of mice and did so with very slow kinetics (Fig. 1D, E) . Moreover, mice injected with TUBO cells exhibited significantly longer median survival times than mice injected with tumorsphere-derived cells (Fig. 1F ).
TUBO and tumorsphere susceptibility to autologous and allogeneic NK cell recognition was initially analyzed in vitro (Fig. 2) . Highly purified autologous and allogeneic NK cells were obtained from the spleens of BALB/c and C57/BL6 mice, respectively. In both experimental settings, tumorspheres were recognized and killed with higher efficiency than TUBO cells ( Fig. 2A,   B ). These observations are in agreement with those previously reported in other human solid tumor experimental systems. [15] [16] [17] 25 In Figure 2 , NK cells were activated with IL2 in vitro, whereas autologous and allogeneic NK cells were used as effectors without any activation in Table 1 . injection of either TUBO or tumorspheres maintain the differences in their expression rates.
Interestingly, we have previously reported that tumorspheres maintain a prevalent CSC phenotype after in vivo injection 27 . As reported in Fig. 4 , a lower frequency of H2-K d and a higher frequency and expression of activating ligands, RAE, H60, PVR and Nectin-2, were observed in both the tumorsphere generated tumors and metastases than in their TUBO generated analogues. Therefore, the immune phenotype that emerges from our data, which is characterized by a reduced number of MHC-I + tumorspheres expressing higher levels of DNAM-1 activating ligands (PVR and Nectin-2), nicely correlates with the higher susceptibility of tumorspheres to NK cell recognition. However, we cannot exclude that in vivo other activating NK receptors besides DNAM-1 may play a role in the tumorsphere higher NK cells susceptibility, as suggested by the increased expression of RAE and H60 by tumorspheres (Fig. 4A ). activating NK cell cytotoxicity with an interferon type I inducer (tilorone). 30 The third group of mice was treated with PBS as a control. Twenty-one days after cell injection, mice were sacrificed and lung metastases were counted and analyzed for size after H&E staining. As reported in Figure   6 , TUBO cell injection gave rise to a higher number of lung metastases in the control groups than in mice injected with tumorspheres ( Fig. 6A, B) . Moreover, the metastasis occupied lung surface was larger in mice injected with TUBO than in mice injected with tumorspheres ( Fig. 6 D-F) , suggesting that the NK cell-mediated elimination of CSCs is more pronounced here than in TUBO cells. NK cell depletion led to an increased number of lung metastases in TUBO, as well as in tumorsphere, injected mice, while NK cell activation by tilorone furnished a beneficial effect by limiting the lung metastatic spread in both experimental groups (Fig. 6A, B) . It can therefore be stated that NK cells control the spread of both cell types in vivo. However, an analysis of the relative NK cell capability to control the metastatic spread of the bulk tumor population and/or CSCs revealed that NK manipulation had a stronger effect on tumorsphere metastatic spread (Fig. 6C) , confirming the importance of NK cells in killing CSCs. This is confirmed by the observation that neither TMβ1 nor tilorone exert any effect on the amount of lung surface occupied by TUBO metastases, while they both significantly modify the area occupied by tumorsphere metastases (Fig. 6D-F) . It should be noted that tumorspheres injected s.c. showed higher tumorigenicity than injected TUBO cells. We can speculate that this difference may reflect the different activation mechanisms that NK cells depend on in the blood and lungs, as reported in BL6 mice for NK cell in vivo control of the melanoma spread in the peritoneum and lung. 31 To understand whether the contrasting findings observed after the intravenous infusion of tumor cells were actually due to differences in NK cells, we analysed their expansion and activation in BALB/c mice injected s.c. and i.v. with either TUBO or tumorspheres, while a further group was left untreated. Mice injected i.v. were sacrificed 21 days after challenge while those injected s.c.
were sacrificed when the tumor reached 5 mm in mean diameter. Blood, lung and tumor NK cell frequencies and activation markers were analyzed. In the blood, CD49b + NK cell frequency increased in the group that received tumorspheres i.v., as compared to all other groups (Fig. 7) .
Moreover, a higher frequency of circulating CD69 + NK cells was found in mice injected with tumorspheres, whether i.v. or s.c., as compared to other groups (Fig. 7) . A detailed analysis of the different NK cell compartments in the blood of mice injected i.v. with either TUBO or tumorspheres was performed and is reported in Figure S4 . It is worth noting that tumorsphere injection did not induce the expansion of T cell subsets (Fig. S5) . The i.v. challenge with breast cancer derived CSCs thus selectively induced the expansion of the activated NK cell compartment, as previously reported in in vitro co-culture experiments conducted using autologous NK cells and human colon adenocarcinoma derived CSCs. 15 However, the lack of Ly49H + in BALB/c mice prevented us from better defining NK cell expansion, i.e. the NK cell memory subset associated with MCMV infected mice. 32 An analysis of the NK cell population infiltrating lung metastases and s.c. tumors revealed that the highest frequency of NK cells was observed in the lungs of mice injected i.v. with tumorspheres ( Fig. 8 C, E) . Interestingly, the NK population was more abundant in lung metastases than in s.c. Fig. 8 A-E) in both mice injected with TUBO and tumorspheres. The evaluation of NK activation displayed a higher percentage of CD69 + cells among the NK cells present in both lung metastases and the tumors of mice injected with tumorspheres than in TUBO-injected mice (Fig. 8 A-E).
tumors (
In conclusion, our data show that in vivo murine breast cancer tumorspheres induce NK cell compartment expansion and promote their activation. Moreover, the in vivo manipulation of NK cell response affects the capability of tumorspheres to undergo lung metastatic spread. It has recently been reported that human ALDH + CSCs, derived from human breast cancer, escape NK recognition by down regulating NKG2D ligands, thanks to the expression of miR20a. 33 Our data in mice expand this finding and indicate that not all breast cancer derived CSCs are resistant to NK cell cytotoxic attack.
Our data corroborate previous in vitro observations obtained using human solid tumors and related CSCs, [12] [13] [14] and strongly suggest that NK cells should be considered a potential useful tool in therapy protocols that aim to target the tumor CSC compartment. haematoxylin and eosin (H&E) stained. 37 Micrometastases were counted on a Nikon SMZ1000 stereomicroscope (Amsterdam, Netherlands), their dimensions measured using ImageJ software and reported as the ratio between the area occupied by metastases and total lung area, as previously described. 
Material and Methods

Cell lines
ErbB2
Tumor and lung dissociation for FACS analysis
Clonal formation assay
TUBO cells and tumorspheres were plated at 1 cell/well in 96-well plates or in 96-well ultra-low attachment plates, containing 150 μl of epithelial or tumorsphere medium, respectively. The number of TUBO or tumorsphere clones generated after 7 days of culture was evaluated and reported as number of clones generated for every 100 single cells seeded.
NK cell isolation
To isolate NK cells, spleens were collected from 8 week-old female BALB/c and C57/BL6 mice Penicillin/Streptomycin. The purity of isolated NK cells was > 95%, as assayed by flow cytometry.
Cytotoxicity assays
Cytotoxic assays were performed using fluorescent 5,6-carboxy-fluorescein-diacetate (CFDA) according to a protocol described elsewhere. 44 Briefly, target cells were labeled with CFDA-mixed isomers (Invitrogen) and then with purified autologous and allogeneic NK effector cells at different 
NK cell immunophenotype
Lymphocytes from the blood of mice were washed twice in PBS and then incubated with erylise buffer (155mM NH 4 Cl, 15.8mM Na 2 CO 3 , 1mM EDTA, pH 7. Differences in mean tumor diameters were calculated using the Student's t test, while differences in tumor incidence and survival were performed using the Mantel-Cox log-rank test. * p<0.05; ** p< 0.01; *** p ≤ 0.001. 
